Science
-
Despite waning headlines, bird flu is still a threat. Here’s how you can help farmworkers.
In the arc of the bird flu in the U.S., 2024 to early 2025 was an explosive time. But then, last month, the CDC announced that it was ending its emergency response to the virus.
-
The crisis is “exasperating”: Long COVID compounds economic hardship in Argentina
Argentina is facing an invisible Long COVID crisis, marked by a lack of clinics, minimal media attention, no disability insurance to help people with the disease cope with their inability to work, and only a couple of Long COVID studies — all amid a 48% cut to the national health budget under President Javier Milei.
-
“The field is coming of age”: Long COVID researchers gather in Santa Fe to foster collaboration
Last week, leading Long COVID and infection-association chronic condition (IACC) researchers met in Santa Fe, New Mexico, for the field’s second Keystone Symposia meeting. They were joined by advocates, clinicians, and representatives from pharmaceutical companies for a three-day conference focused on sharing new research and building consensus.
-
Research updates, August 19
A new preprint from the National Institutes of Health (NIH) RECOVER study found that COVID reinfections may increase the risk of Long COVID by about 35%.
-
No “easy home runs”: Early Long COVID trials of Paxlovid and monoclonal antibodies failed, but the treatments still have potential
While three early clinical trials of these drugs did not find they led to health improvements for participants, further trials are getting more intentional in targeting viral persistence.
-
Research updates, August 12
People with myalgic encephalomyelitis (ME) have significant genetic differences in their DNA, according to a preprint shared this week from the DecodeME study.
-
Three clinical trials for Long COVID are testing JAK inhibitors to treat immune dysregulation
Three separate trials are testing the immunomodulator drugs abrocitinib (Cibinqo), baricitinib (Olumiant), and upadacitinib (Rinvoq). All are JAK inhibitors, which target specific inflammation pathways.
-
Research updates, August 5
A drug originally developed for celiac disease was found to be safe and effective in treating a post-COVID syndrome in children, according to a new paper published in Science Translational Medicine.
-
Clinical trials are testing cancer drug rapamycin for Long COVID and ME
Two clinical trials are currently underway in the U.S. to evaluate the effect of rapamycin on Long COVID and myalgic encephalomyelitis (ME) — one at Mount Sinai’s Cohen Center for Recovery from Complex Chronic Illness and another at Simmaron Research.
-
Research updates, July 29
Two studies on potential biomarkers for myalgic encephalomyelitis (ME) were published this month. Plus, new studies about stellate ganglion blocks.
Follow Us
get the latest long covid news
Trending
Recent ARTICLES
-
Trans people with Long COVID navigate a new “dark age” in trans health
-
National COVID-19 trends, October 13
-
Research updates, October 13
-
How I built a COVID-safer school that’s become the heart of a more caring community
-
Biological pathways and mechanistic trials centered at new Long COVID conference in Amsterdam
Tags
advocacy arts CDC clinical trials commentary COVID-19 precautions disability essay government policy H5N1 healthcare HHS influenza international Long COVID in children masks and respirators ME ME/CFS medical education national COVID-19 trends NIH NIH RECOVER podcast public health research update science Trump administration updates and events vaccines wastewater surveillance